1
|
Ruiz-Peñaloza MA, López-Tiro JJ, Ortíz-Monteón ZE, García-Rosas C. [Control de asma grave predominantemente eosinofílica con el uso de anti IL-5]. Rev Alerg Mex 2023; 70:199. [PMID: 37933940 DOI: 10.29262/ram.v70i3.1269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2023] Open
Abstract
Background Asthma is a chronic inflammatory disease of the airways, caused by inflammatory cells and mediators, associated with smooth muscle dysfunction, causing variable airflow obstruction. With high, low and mixed type 2 immunoinflammatory mechanisms (endotypes). Severe asthma is that which requires step 4 or 5 of treatment (GINA 2023). The TH2 High phenotype, non-allergic with eosinophilia and FENO, is the second most common. It affects 300 million people around the world. Objetive Describe asthma biomarkers after the use of antiinterleukin 5, Benralizumab, in adults with severe asthma. Methods Case report, descriptive study. Patients with severe eosinophilic asthma and chronic polyposis rhinosinusitis under treatment with anti-IL5 were included, evaluating inflammatory biomarkers. Results Serum eosinophils, FENO, ACT, spirometry, and exacerbations were measured in 8 patients at baseline and 6 months after treatment. The FEV1-FVC was 51% with improvement up to 95% later. 5 patients had FENO > 45 ppm subsequently only 3 continued to be inflamed. Eosinophilia 150 cells and subsequently only 1 patient persisted with eosinophilia 200 cells. Initial ACT < 19 in 7 patients Final ACT >19 in 7 patients. Exacerbations 8 patients with 2 or more exacerba- tions subsequently only 1 patient presented exacerbation. Conclusion The use of anti-interleukin 5 (benralizumab) does reduce inflammatory markers, improves control and number of exacerbations in the short term. Monoclonal antibodies (Anti IL-5), if they improve inflammatory biomarkers, if clinical characteristics and inflammatory biomarkers are taken into account, it favors adequate asthma control.
Collapse
|
2
|
Mattei L, Suehs CM, Alagha K, Bourdin A, Brousse C, Charriot J, Devouassoux G, Fry S, Guilleminault L, Gouitaa M, Taille C, Chanez P, Pahus L. Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study. Ther Adv Respir Dis 2021; 15:17534666211049735. [PMID: 34629000 PMCID: PMC8504226 DOI: 10.1177/17534666211049735] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background: Current practices for assessing response to anti-interleukin 5/R treatment in severe asthma patients are heterogeneous. The objective of this study was to achieve an expert consensus defining failure criteria for anti-interleukin 5/R treatment in severe asthma patients. Methods: Experts were invited to a 5-round Delphi exercise if they were pulmonologists managing ⩾30 patients at a nationally recognized severe asthma expert centre. Following two rounds of statement-generating brainstorming, the expert panel ranked each statement according to a 5-point Likert-type scale during three additional rounds. Positive consensus was considered achieved when ⩾80% of experts agreed with a statement with >50% strong agreement and <15% disagreement. Results: Twenty experts participated in the study. All experts agreed that predefined treatment goals defining effectiveness should be personalized during shared decision making via a patient contract. Treatment failure was defined as (1) absence of a reduction in exacerbation rates by ⩾25% or (2) absence of a reduction in oral corticosteroid therapy by ⩾25% of the initial dosage or (3) occurrence of emergency room visits or hospitalizations after 6 months of treatment. Treatment failure should result in discontinuation. For partial responders, treatment discontinuation was not recommended unless an alternative from another therapeutic class exists and should be discussed in a multidisciplinary consultation. Conclusion: The present study provides objective criteria for anti IL5 or IL5R failure in severe asthma and suggests consensus based guidelines for prescription, evaluation and discontinuation decision-making.
Collapse
Affiliation(s)
- Laura Mattei
- Aix Marseille Univ., APHM, Clinique des bronches, de l'allergie et du sommeil, Hôpital Nord, Chemin des Bourrely, 13015 Marseille, France
| | - Carey M Suehs
- Department of Respiratory Diseases, Univ. Montpellier, CHU Montpellier, Montpellier, France.,Department of Medical Information, Univ. Montpellier, CHU Montpellier, Montpellier, France
| | - Khuder Alagha
- Department of Respiratory Diseases, Univ. Montpellier, CHU Montpellier, Montpellier, France.,Clinique du Parc, Castelnau-le-Lez, France
| | - Arnaud Bourdin
- Department of Respiratory Diseases, Univ. Montpellier, CHU Montpellier, Montpellier, France.,PhyMedExp, CNRS, INSERM, Univ. Montpellier, CHU Montpellier, Montpellier, France.,Clinical Research Initiative In Severe Asthma: a Lever for Innovation & Science (CRISALIS), F-CRIN Network, INSERM US 015, Toulouse, France
| | - Christophe Brousse
- Department of Respiratory Diseases, Univ. Montpellier, CHU Montpellier, Montpellier, France.,Clinique du Parc, Castelnau-le-Lez, France
| | - Jeremy Charriot
- Department of Respiratory Diseases, Univ. Montpellier, CHU Montpellier, Montpellier, France.,PhyMedExp, CNRS, INSERM, Univ. Montpellier, CHU Montpellier, Montpellier, France
| | - Gilles Devouassoux
- Clinical Research Initiative In Severe Asthma: a Lever for Innovation & Science (CRISALIS), F-CRIN Network, INSERM US 015, Toulouse, France.,Hôpital de la Croix-Rousse, Service de Pneumologie, Hospices Civils de Lyon, Lyon, France.,Inflammation and Immunity of the Respiratory Epithelium-EA7426 (PI3)-South Medical University Hospital-Lyon 1 Claude Bernard University, Pierre-Bénite, France
| | - Stephanie Fry
- Clinical Research Initiative In Severe Asthma: a Lever for Innovation & Science (CRISALIS), F-CRIN Network, INSERM US 015, Toulouse, France.,CHU Lille, Service de Pneumologie et Immuno-allergologie, Institut Pasteur Lille, Univ. Lille, Lille, France
| | - Laurent Guilleminault
- Clinical Research Initiative In Severe Asthma: a Lever for Innovation & Science (CRISALIS), F-CRIN Network, INSERM US 015, Toulouse, France.,Department of Respiratory Medicine, Toulouse University Hospital Centre, Toulouse, France.,Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Inserm U1291, University of Toulouse, CNRS U5282, Toulouse, France
| | - Marion Gouitaa
- Aix Marseille Univ., APHM, Clinique des bronches allergies et sommeil, Marseille, France
| | - Camille Taille
- Clinical Research Initiative In Severe Asthma: a Lever for Innovation & Science (CRISALIS), F-CRIN Network, INSERM US 015, Toulouse, France.,Groupe Hospitalier Universitaire AP-HP Nord-Université de Paris, Hôpital Bichat, Service de Pneumologie et Centre de Référence constitutif des Maladies Pulmonaires Rares, Inserm UMR 1152, Paris, France
| | - Pascal Chanez
- Aix Marseille Univ., APHM, Clinique des bronches allergies et sommeil, Marseille, France.,Clinical Research Initiative In Severe Asthma: a Lever for Innovation & Science (CRISALIS), F-CRIN Network, INSERM US 015, Toulouse, France.,Aix Marseille Univ., INSERM U1263, INRA 1260 (C2VN), Marseille, France
| | - Laurie Pahus
- Aix Marseille Univ., APHM, Clinique des bronches allergies et sommeil, Marseille, France.,Clinical Research Initiative In Severe Asthma: a Lever for Innovation & Science (CRISALIS), F-CRIN Network, INSERM US 015, Toulouse, France.,Aix Marseille Univ., INSERM U1263, INRA 1260 (C2VN), Marseille, France.,Aix Marseille Univ., CNRS, EFS, ADES, Marseille, France
| |
Collapse
|
3
|
Renz H, Bachert C, Berek C, Hamelmann E, Levi-Schaffer F, Raap U, Simon HU, Ploetz S, Taube C, Valent P, Voehringer D, Werfel T, Zhang N, Ring J. Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI. Scand J Immunol 2021; 93:e13032. [PMID: 33624312 DOI: 10.1111/sji.13032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Revised: 02/10/2021] [Accepted: 02/21/2021] [Indexed: 12/15/2022]
Abstract
Over the last century, eosinophils have been regarded ambiguously either as 'friends' or 'foes'. Recent developments have greatly enhanced our understanding of the role and function of eosinophils in health and disease. Pathogenic eosinophilic inflammation can lead to severe diseases in various organs, such as the gastrointestinal tract, airways, heart and skin. In a 2-day focus workshop of the German Society for Allergology and Clinical Immunology (DGAKI), the state of the art was discussed and practical recommendations for diagnosis and treatment of eosinophilic diseases, with a particular focus on new biologics, such as anti-interleukin 5 and anti-interleukin 5R, were derived.
Collapse
Affiliation(s)
- Harald Renz
- Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL), Philipps Universität Marburg, Marburg, Germany
| | - Claus Bachert
- Upper Airways Research Laboratory and Department of Oto-Rhino-Laryngology, Ghent University and Ghent University Hospital, Ghent, Belgium.,Division of ENT Diseases, CLINTEC, Karolinska Institute, University of Stockholm, Stockholm, Sweden
| | - Claudia Berek
- Deutsches Rheuma Forschungszentrum, Ein Institut der Leibnizgemeinschaft, Berlin, Germany
| | - Eckard Hamelmann
- Klinik für Kinder- und Jugendmedizin, Evangelisches Klinikum Bethel, Bielefeld, Germany.,Allergy Center of the Ruhr University, Bochum, Germany
| | - Francesca Levi-Schaffer
- School of Pharmacy, Faculty of Medicine, The Institute for Drug Research, The Hebrew University of Jerusalem, Israel
| | - Ulrike Raap
- Clinics of Dermatology and Allergy, Faculty of Medical Health and Sciences, University of Oldenburg, Germany
| | - Hans-Uwe Simon
- Institute of Pharmacology, University of Bern, Bern, Switzerland
| | | | - Christian Taube
- Department of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, Essen, Germany
| | - Peter Valent
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, and Ludwig Boltzmann Institute for Hematology & Oncology, Medical University of Vienna, Vienna, Austria
| | - David Voehringer
- Department of Infection Biology, University Hospital Erlangen and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - Thomas Werfel
- Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover, Hannover, Germany
| | - Nan Zhang
- Upper Airways Research Laboratory and Department of Oto-Rhino-Laryngology, Ghent University and Ghent University Hospital, Ghent, Belgium
| | - Johannes Ring
- Deptment of Dermatology and Allergology Biederstein, Technical University Munich (TUM), Munich, Germany
| |
Collapse
|
4
|
Tsukamoto N, Takahashi N, Itoh H, Pouliquen I. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects. Clin Pharmacol Drug Dev 2015; 5:102-8. [PMID: 27138023 PMCID: PMC5042051 DOI: 10.1002/cpdd.205] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2015] [Accepted: 06/04/2015] [Indexed: 01/16/2023]
Abstract
Interleukin 5 (IL‐5) and eosinophils are thought to play an important role in the pathology of asthma. This study evaluated the pharmacokinetics, pharmacodynamics, safety, and tolerability of mepolizumab, a humanized anti‐IL5 IgG1 monoclonal antibody, in development for the treatment of severe eosinophilic asthma. This single‐blind study randomized 35 healthy Japanese male subjects (3:1) to receive either a single mepolizumab intravenous dose (10, 75, 250, or 750 mg) or placebo. Subjects were observed for up to 151 days postdose, depending on the dose administered. Blood samples were collected to measure mepolizumab concentrations, blood eosinophils, IL‐5, and antibodies to mepolizumab. Mepolizumab exhibited dose‐proportional pharmacokinetics. The terminal phase half‐life was 19.7–34.6 days, independent of dose. Higher mepolizumab plasma concentrations were associated with lower blood eosinophil counts. Mepolizumab 75–750 mg reduced blood eosinophils for ≥3 months postdose. Mepolizumab demonstrated a favorable safety profile: of 41 reported adverse events, most were mild in severity and none were serious. No neutralizing antibodies to mepolizumab were detected. Sustained reduction in blood eosinophils after single intravenous mepolizumab doses ≥ 75 mg, along with mepolizumab pharmacokinetics and a favorable tolerability profile in healthy Japanese subjects, provides a solid foundation for future studies with mepolizumab in Japanese patients with asthma.
Collapse
Affiliation(s)
- Naohiro Tsukamoto
- Dermatology, Stiefel, Medicines Development, Japan Development & Medical Affairs DivisionGlaxoSmithKline K.K.TokyoJapan
| | - Naoki Takahashi
- Clinical Pharmacology, Medicines Development, Japan Development & Medical Affairs DivisionGlaxoSmithKline K.K.TokyoJapan
| | - Hiroshi Itoh
- Biomedical Data Sciences Department, Japan Development & Medical Affairs DivisionGlaxoSmithKline K.K.TokyoJapan
| | | |
Collapse
|
5
|
Abstract
Several lines of evidence suggest that deficiency of eosinophils is not associated with any characteristic abnormality. Patients lacking eosinophils, in the setting of immunodeficiency or as a consequence of IgG-mediated eosinophil precursor destruction, do not display any distinguishing abnormalities related to eosinophil reduction. The observation that eosinophil-deficient mice do not display any distinctive syndrome or failure of their health is evidence that, under ordinary laboratory conditions, the eosinophil does not play a critical role in the well-being of mammals. Observations that monoclonal antibodies to interleukin-5 (IL-5) are well tolerated appear unsurprising in light of these findings. For example, patients with the hypereosinophilic syndrome have received mepolizumab, an anti-IL-5 monoclonal antibody, for as long as 6 years and have not developed any characteristic set of adverse events. Safety data for reslizumab, another anti-IL-5 monoclonal antibody, and benralizumab, a monoclonal antibody to the IL-5 receptor α-chain, are comparatively limited, especially for benralizumab, although reports of administration of these antibodies to humans suggest that they are well tolerated. Thus, data to the present suggest that reduction of eosinophils appears to have no characteristic ill effects on normal health, and monoclonal antibodies that deplete eosinophils have the potential to be widely employed in the treatment of eosinophil-associated diseases.
Collapse
Affiliation(s)
- G. J. Gleich
- University of Utah Health Sciences Center; Salt Lake City; UT; USA
| | - A. D. Klion
- National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda; MD; USA
| | - J. J. Lee
- Department of Biochemistry and Molecular Biology; Mayo Clinic Arizona; Scottsdale; AZ; USA
| | - P. F. Weller
- Beth Israel Deaconess Medical Center; Harvard Medical School; Boston; MA; USA
| |
Collapse
|